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ABSTRACT 
 
Background: Acute myocardial infarction is a myocardial necrosis associated with acute 
myocardial ischemia of which the incidence keeps increasing over time. Appropriate management 
of acute myocardial infarction is very important in order to determine the efficacy of the therapy 
and also to prevent further complications due to acute myocardial infarction. Captopril is essential 
in the management of acute myocardial infarction to inhibit the renin-angiotensin-aldosterone 
system whereby aldosterone may increase the probability of heart failure and increase mortality up 
to approximately 10 times compared to patients with acute myocardial infarction without heart 
failure. The administration of captopril should be uptitrated the doses in order to obtain optimal 
results, however there is no such fixed standard on how fast the doses of captopril should be 
uptitrated in order to obtain a more optimal effect, especially in order to suppress the plasma 
aldosterone level. This study examined the effect of rapid uptitration of captopril in the first 3 days 
of treatment of patients with acute myocardial infarction on plasma aldosterone levels compared to 
the increase in the captopril standard uptitration. 
Subjects and Method: This is an experimental research with Randomized Controlled Trial 
(RCT). 28 patients with Acute Myocardial Infarction on Cardiovascular Intensive Care Unit 
(ICVCU) and Cardiovascular wards of RSUD Dr. Moewardi hospital Surakarta were sequentially 
involved as research subjects and then randomly divided into a control group who received 
standard captopril uptitration and treatment group who received captopril rapid uptitration. The 
blood plasma was taken on the first day before the administration of captopril and on the last day 
of treatment. The plasma aldosterone level was tested by ELISA. Independent t-tests were carried 
out for data that qualified the normality test and mann whitney test if not qualified in the normality 
test with kolmogorov smirnov. It was considered statistically significant if the value of p < 0.05. 
Results: Plasma Aldosterone levels in treatment group was lower than control group and 
statistically significant (1133.54 ± 748.81 pg/dl vs 512.16 ± 444.81 pg/dl; p= 0.013 ) 
Conclusion: Treatment with captopril rapid uptitration can decrease aldosterone plasma levels 
lower than captopril with standard uptitration in patient with acute myocardial infarction. 
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BACKGROUND 
Acute Myocardial infarction is a term for 
the occurrence of necrosis within a consist-
ent definition related to acute myocardial 
ischemia. Acute myocardial infarction is in-
dicated by the increasing of biomarker  es-
pecially heart  troponin. Acute myocardial in-
farction itself can be divided into acute myo-
card infarction with ST segment elevation 
on at least 2 electrocardiography (EKG) 
leads that are connected and acute myo-
cardial infarction without ST segment ele-
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vation (Thygesen K, 2012). The frequency of Coronary Heart Disease incidents (CHD) 
are getting increasing by time, based on 
data of Riskesdas 2013, Coronary Heart Di-
sease prevalence in Indonesia based on 
diagnosis also symptoms is around 0.5%-
1.5% (Kementerian Kesehatan RI, 2013).  
The right management of acute myo-
cardial infarction is very important in de-
termining the success of therapy and also 
preventing further complication as the re-
sult of acute myocardial infarction (Hamm, 
2012). ACE inhibitor is very important in 
the management of acute myocardial infarct-
ion to hamper renin angiotensin aldoster-
one system in which it is identified that the 
activation of renin angiotensin aldosterone 
system may increase the possibility of heart 
failure occurrence and on the patients of 
acute myocardial infarction that coincides 
with heart failure it will increase the mor-
tality rate about 10 times compared to pa-
tients of acute myocardial infarction with-
out heart failures (Juilliere, 2012). 
The final product renin angiotensin 
aldosterone system is aldosterone in which 
aldosterone may give effect directly to car-
diovascular system. Aldosterone directly 
may lead to proliferation of heart myocyte 
and fibroblast that will give inflammation 
response through TGF-β and cell death  
(White, 2003). Study about aldosterone on 
acute myocardial infarction firstly conduct-
ed in 2006 by Beygui et al, in which high 
level of plasma aldosterone on patients who 
are diagnosed with acute myocardial in-
farction with ST segment elevation  is relat-
ed to the increasing number of death which 
is not related to age, heart failure, and re-
perfusion status (Beygui, 2006). 
The higher level of plasma aldoster-
one on patients of coronary heart disease 
and acute myocardial infarction have a re-
lationship with the increasing number of 
death and the occurrence of acute ischemia 
incidents in which it shows the big effect of 
plasma aldosterone level in the process of 
hearth disease especially coronary heart di-
sease (Mignano, 2014). The negative effect 
of aldosterone itself has been identified that 
can be inhibited by medication that may 
hamper renin angiotensin aldosterone sys-
tem among others are renin inhibitor such 
as aliskiren, ACE inhibitor such as capto-
pril, inhibitor of AT1 receptor such as val-
sartan, as well as inhibitor of mineralocor-
ticoid receptor such as spironolactone (Pitt, 
2012).  
Inhibition of renin angiotensin system 
and aldosterone within the management of 
myocardial infarction since aldosterone is 
the main mineralocorticoid hormone which 
is secreted by adrenal cortex and as the key 
modulator of neurohormonal hemodynam-
ic arrangement (Udell, 2013). The previous 
study obtained the increasing of plasma 
aldosteron post acute myocardial infarction 
will increase the risk of heart failure and 
death in the future (Ivanes, 2012).  
The guidelines of acute myocardial in-
farction management according to AHA as 
well as ESC suggests the administration of 
ACE inhibitor as a therapy given to acute 
myocardial infarction patients and the ad-
ministration of ACE inhibitor should be con-
ducted  with gradual dosage increasing to 
attain optimal result in the inhibition of renin 
angiotensin aldosterone system, yet there is 
no standard regulation how fast the dosage 
increasing of ACE inhibitor shoulf be con-
ducted to get more optimal effect especially 
in keeping down the level of plasma 
aldosterone (Hamm, 2012; O’Gara, 2013). 
Up to currently Captopril is still recommend-
ed by AHA in the regular management of 
acute myocardial infarction which is started 
with initial dosage of 6.25 mg or 12.5 mg 
and it is possible to be titrated up to 25 mg 
or 50 mg in accordance with patients’ to-
lerance limit (O’Gara, 2013). 
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SUBJECTS AND METHOD 
This study was conducted in  Intensive Car-
diovascular Care Unit and ward of RSUD 
Dr. Moewardi Surakarta during Februari 
2016-Maret 2016. The type of the study was 
Randomized Controlled Trial. Patients who 
came consecutively, were put into two dif-
ferent groups. Treatment group wasa group 
of acute myocardial infarction patients who 
got the rapidly increased titration of capto-
pril with optimal dosage ≥75 mg/ day with-
in three day treatment in  ICVCU and cont-
rol group that got standard increased titrat-
ion of captopril 37.5 mg/day in the third 
day of treatment in ICVCU. Intervention 
was conducted with undercover technique 
called single blind, in which subjects did 
not know the type of treatment, whereas 
researchers knew the type of treatment. 
Subjects were AMI patients with ST seg-
ment elevation and without ST segment ele-
vation in RSUD Dr. Moewardi Surakarta 
and the administration of captopril with 28 
subjects. 
 
Inclusion Criteria  : 
1. All AMI patients (killip 1-3) 
2. Level of creatinine ≤2.5 mg/dl, level of 
potassium ≤5.0 mmol/l, TDS ≥90 mm 
Hg with stable hemodynamic  
3. Did not get inhibitor of RAA system pre-
viously  
Exclusion Criteria :  
1. Patients with history of heart failure or 
AMI previously  
2. Creatinine level  >2.5 mg/dl, potassium 
level  >5.0 mmol/l 
3. Cardiogenic shock (killip IV), TDS <90 
mmHg, hemodynamic was not stable 
4. Obtain RAA system inhibitor prior to 
attack or need other RSS system inhibit-
or in addition to captopril during the 
treatment 
5. Die within 6 days of treatment 
Definition of Operational Variables 
1. Standard uptitration: it starts with do-
sage 6.25 mg of captopril 3 times a day 
and titrated into 12.5 mg 3 times a day 
for 3 days of treatment. 
2. Rapid uptitration it starts with dosage 
12.5 mg 3 times a day and titrated into 
optimal dosage 25 mg or 50 mg 3 times a 
day for 3 days of treatment. 
 
Statistical Analysis 
Data were presented in a form of  mean ± 
SD afterward they were analyzed by using  
SPSS 22.0 for windows with value p<0.05 
was considered statistically significant. Test 
for differences between means was employ-
ed. To know the differences of mean bet-
ween control group and treatment group 
also before and after the treatment, in-
dependent t sample test was used if the 
data distribution was normal (if it was not 
normal Mann Whitney test was employed). 
 
RESULTS 
The study aimed to know the influence of 
rapid uptitration of captopril toward the 
level of plasma aldosterone on acute myo-
cardial infarction patients. The study was 
conducted from February 2016 up to March 
2016 on 28 patients of acute myocardial 
infarction who got captopril in ICVCU and 
ward of RSUD Dr. Moewardi Surakarta. 
The number of research subjects was 28, 
divided into two groups of samples that 
were treatment group which consists of 14 
people and control group which consists of  
14 people. In this study treatment group 
was given captopril with rapid titration 
during the treatment in ICVCU, whereas 
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control group got captopril with standard 
titration which was regularly given in 
RSDM. 
Data of research subjects’ basic cha-
racteristics that were constant in nature 
were tested in term of their normality using 
Kolmogorov-Smirnov test to assess data 
normality and followed by test for mean 
differences by suing independent t-test if 
the data were normal in nature to test 
whether there was significant difference 
between two groups of samples. If the data 
were not normal in nature, then to test 
whether there was significant difference 
between two groups of sample, a test for 
mean differences was conducted by using  
Mann Whitney. To test whether there was a 
significant difference between two groups 
of sample that were binominal in nature 
then non-parametric comparative test was 
conducted using Chi-Square. Basic charac-
teristics of patients can be seen in Table 1. 
 
Table 1. Basic characteristics of research subjects 
Variables 
Treatment(n = 15) 
(mean, SD) 
Control (n = 15) 
(mean, SD) 
p 
Age (year) 61.50 ± 9.73 57.71 ± 11.51 0.356 
Male, n (%) 9 (64) 10 (71) 0.686 
Risk Factors 
Hypertension, n (%) 
DM, n (%) 
Dyslipidemia, n (%) 
Smoking, n (%) 
 
7 (50) 
10 (71) 
9 (64) 
10 (71) 
 
6 (43) 
5 (38) 
8 (57) 
9 (64) 
 
0.705 
0.058 
0.699 
0.686 
Hemoglobin 13.51 ± 1.23 12.82 ± 1.36 0.170 
Total cholesterol 180.14 ± 28.6 185.50 ± 44.07 0.706 
Triglyceride 134.76 ± 47.7 141.64 ± 46.41 0.703 
LDL 
HDL 
113 ± 32.85 
37.5 ± 7.41 
115.79 ± 29.82  
33.36 ± 9.37 
0.816 
0.206 
STEMI, n (%) 
Creatinine before 
Creatinine after 
Potassium before 
Potassium after 
Troponin before 
Troponin after 
Delta troponin 
11 (76) 
1.18 ± 0.4 
0.99 ± 0.28 
3.81 ± 0.54 
3.94 ± 0.24 
11.57 ± 12.23 
9.04 ± 7.93 
-2.54 ± 8.82 
10 (71) 
1.36 ± 0.56 
1.11 ± 0.38 
3.71 ± 0.77 
3.8 ± 0.27 
6.25 ± 9.86 
7.50 ± 8.24 
1.25 ± 8.62 
0.663 
0.320 
0.345 
0.694 
0.153 
0.232 
0.890 
0.261 
To measure the level of plasma aldosterone towards captopril on control group and treatment 
group can be seen in table 2-5. 
 
Table 2. Level of  plasma aldosterone before captopril administration on treat-
ment group and control group 
Variable Treatment Control 
Mean 
Difference 
Std. Error 
Difference 
p 
95% CI 
Lower Upper 
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Aldosteron
e (pg/dl) 
1400.18 ± 
820.37 
1202.81 ± 
869.69 
-197.37 319.53 0.542 -854.16 459.43 
Table 3.  Level of plasma aldosterone after and before the administration of cap-
topril with rapid uptitration on treatment group 
Variable 
After 
captopril 
Before  
captopril 
Mean 
Difference 
Std. Error 
Difference 
p 
95% CI 
Lower Upper 
Aldosteron
e (pg/dl) 
356.8 ± 
258.95 
1400.18 ± 
820.37 
1043.37 172.11 <0.001 671.55  1415.2 
 
Table 4. Level of plasma aldosterone after and before the administration of 
captopril with standard uptitration on control group 
Variable 
After 
captopril 
Before 
captopril 
Mean 
Difference 
Std. Error 
Difference 
p 
95% CI 
Lower Upper 
Aldosteron 
(pg/dl) 
697.8 ± 
555.92 
1202.81 ± 
869.68 
  505.01 122.91 <0.001 239.48  770.55 
 
Table 5. Level of plasma aldosterone after the administration of captopril on 
treatment and control groups 
Variable Treatment Control 
Mean 
Difference 
Std. Error 
Difference 
p 
95% CI 
Lower Upper 
NO (µM) 356.80 ± 
258.95 
697.8 ± 
55.,92 
340.99 163.9 0.047 4.09 677.9 
 
Table 6. Inhibition on the increase of plasma aldosterone level on treatment 
group and control group 
Variable Treatment Control 
Mean 
Difference 
Std. Error 
Difference 
p 
95% CI 
Lower Upper 
Aldosteron
e (pg/dl) 
1133.54 ± 
748.81 
512.16 ± 
444.81 
-621.38 232.77 0.013 -1099.86 -142.91 
The result shows that test for mean 
difference by using  independent t-test in-
dicates or can be implied that the reduction 
of plasma aldosterone level on treatment 
group is lower than the reduction of plasma 
aldosterone level on control group and the 
difference is statistically significant. 
 
DISCUSSION 
The study was an experimental study that 
aimed to seek the effect of rapid uptitration 
of captopril toward plasma aldosterone le-
vel on acute myocardial infarction patients. 
Acute myocardial infarction is an incident 
of myocardium necrosis within a situation 
which is consistent with acute myocardial 
ischemia (Thygesen, 2012). A proper ma-
nagement of acute myocardial infarction is 
very important in determining therapy 
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accomplishment and also preventing furth-
er complication as the result of acute myo-
cardial infarction (Hamm, 2012). 
Captopril administration to patients 
with acute myocardial infarction has been 
proven in reducing the occurrence of dila-
tation on left ventricle without having sig-
nificant hypotension effect (Ray, 1993), cap-
topril is also able to prevent extension of in-
farction and maintaining electrical stability 
post acute myocardial infarction compared 
to regular therapy with nitroglycerine and 
thrombolysis (Bussmann,  1995). Captopril up 
to currently is still recommended by AHA 
in regular management of acute myocardial 
infarction patients started from initial dos-
age of 6.25mg or 12.5 mg and it is possible 
to be titrated up to  25mg or 50mg in ac-
cordance with patients’ tolerance limit (O’-
Gara, 2013). 
Aldosterone is a mediator of vascular 
and myocardial remodeling also contributes 
in preventing synthesis of nitric oxide (NO), 
endothelium dysfunction and myocardial 
stiffness. Activation of renin angiotensin al-
dosterone system both locally and systemic-
ally will lead to the significant increase of 
aldosterone and generate deterioration of 
heart function because of the effect which is 
caused by aldosterone. 
High dosage of captopril is told to be 
able to reduce the level of aldosterone plas-
ma on heart failure patients better than low 
dosage of captopril. High dosage of capto-
pril is defined as ≥75mg/ day and low dos-
age of captopril is defined as <75mg/ day. 
The inhibition of plasma aldosterone level 
is found in the administration of high dos-
age of captopril (Pacher, 1993). Dosage of 
captopril should be increased by titration, 
so far the guidelines of captopril uptitration 
only occurs on heart failure which by stand-
ard is increased after 2-4 weeks on out-
patients, however it can be increased faster  
on inpatients (Siswanto, 2015), though, there 
is no standard on how fast the increase of 
captopril titration on acute coronary syn-
drome. 
So far captopril is a type of ACE in-
hibitor which is always available in RDM and 
also a formulation of ACE inhibitor which is 
available in peripheral hospitals in Indo-
nesia so that the administration of captopril 
with rapid uptitration is extremely possible 
to be applied in other hospitals in Indo-
nesia. In the guideline of captopril admini-
stration it is mentioned that according to 
AHA there is no specific regulation on the 
best practice for captopril uptitration for ar-
riving at the optimal dosage that patients 
can tolerate (O’Gara, 2013). The guidelines 
give privilege to each doctor to conduct ti-
tration in accordance with patients’ condi-
tion however if it is possible the study is ex-
pected to be consideration to conduct capto-
pril rapid titration as long as it is within 
patients’ tolerance. 
The study also conducted evaluation to 
discover the safety level of captopril rapid 
uptitration administration. In accordance 
with the guidelines of AHA (O’Gara, 2013) 
that during the administration of captopril, 
an evaluation toward kidney function and 
potassium level should be performed to 
discover the reduction of kidney function 
and electrolyte disorder since captopril is 
mainly discarded through kidney  (Brown, 
1998).  
The study proved that captopril ad-
ministration with captopril rapid titration 
on treatment group did not have any sig-
nificant difference statistically towar kidney 
function reduction and potassium increase 
compared to captopril standard titration on 
control group. The result of the study is 
important considering that the optimal dos-
age administration of captopril is difficult 
to attain for the side effect that make 
doctors often limit captopril up to standard 
dosage 3x12.5mg which does not fit with 
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the recommended guidelines by AHA. Prev-
ious study had proven that captopril is safe 
in term of the effect on blood pressure so it 
will not lead to significant hypotension ef-
fect on acute myocardial infarction patients 
(Ray, 1993) and the study added that capto-
pril rapid uptitration did not generate kid-
ney disorders potassium increase effect on 
acute myocardial infarction patients. The 
study also attempted to give description on 
whether there was a correlation between 
captopril rapid uptitration toward troponin 
level. Troponin is acknowledged as heart 
biomarker that may become projection of 
heart muscle damage so it is also possibly 
affected by the administration of captopril. 
The study proved that there was no sig-
nificant correlation between captopril ad-
ministration with rapid uptitration toward 
troponin level. It is possibly caused by pa-
tients’ characteristics differences in patients 
who receive reperfusion therapy and those 
who do not will have different changes in 
troponin level (Makam, 2015) so that there 
will be extremely various dissimilarity of 
troponin level alteration on acute myo-
cardial infarction patients and also varied 
onset presentation of acute myocardial 
infarction attack on patients in this study 
generated invalid troponin level to be com-
pared with captopril uptitration. It may 
need other studies that focus to evaluate 
troponin toward captopril with homogen 
samples who have received reperfusion 
therapy. Aldosterone has an advantage in 
evaluating therapy administration on acute 
myocardial infarction patients compared to 
other biomarkers such as troponin. It hap-
pens since the troponin level can not be 
evaluated if it exceeds acute heart attack 
phase in which the level of troponin is 
decreasing to normal after 7 days and will 
rapidly decrease if receives reperfusion 
therapy (Mahajan, 2011), it is different with 
aldosterone level that will remain assess-
able although it has past acute myocardial 
infarction phase, it is because aldosterone is 
hormone within circulation whose level re-
main measurable when it pasts acute phase, 
it will remain increasing even when the 
patient endures heart failure (Pitt, 2012; 
Hurwitz, 2004).  
The administration of ACE inhibitor 
in which the study used captopril is ac-
knowledged as capable of reducing plasma 
aldosterone well by administrating capto-
pril with either rapid uptitration or stand-
ard uptitration. It proves that the adminis-
tration of captopril is proven to have good 
effect in the inhibition of renin angiotensin 
aldosterone, so that it meets both AHA and 
ESC guidelines that catopril administration 
should be given with recommendation class 
1A to patients of STEMI anterior, heart fai-
lure, and fraction ejection <40%, recom-
mendation class IIa LoE B to all STEMI ex-
cluding anterior, and recommendation IB 
to NSTEMI.  
The previous study had showed that 
the optimal dosage of captopril adminis-
tration ≥75 mg/day is able to reduce the 
level of plasma aldosterone better than 
dosage which is not optimal <75 mg/ hari 
(Bussmann, 1995; Pacher, 1993). The study 
showed that optimal dosage which is im-
mediately given with rapid uptitration of 
captopril is able to reduce the level of plas-
ma aldosterone better compared to capto-
pril administration with standard uptitrat-
ion. The researchers expect that the study 
may open new insights and becomes the 
consideration to the importance of optimal 
dosage captopril administration on acute 
myocardial infarction patients the faster 
catopril is increased up to optimal dosage 
the faster it reduces the level of plasma 
aldosterone. The study is quite easy to 
conduct and possible to be applied in all 
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heart centers that employ captopril as ACE 
inhibitor post acute myocardial infarction. 
The study had a limit that did not dis-
tinguish whether patients received reper-
fusion therapy or not, thus it did not dis-
cover whether reperfusion also affected on 
the reduction of plasma aldosterone level. 
The study was only on one center, it needs 
to conduct on multicenter especially on 
center which still use captopril, as ACE 
inhibitor, with more number of sample so 
that can enhance the influence of the study. 
Captopril administration with rapid up-
titration will better reduce the level of plas-
ma aldosterone compared to standard up-
titration of captopril on acute myocardial 
infarction patients. 
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